were assessed using polysomnography9 and simultaneous monitoring by the Autoset (ResCare UK Ltd, Oxford, UK). The Autoset measures pressure in the anterior nares using nasal cannulae connected to a pressure manometer. Anterior nares pressure reflects flow and the flow/time profile is examined using software (ResCare Autoset version 2.0) in a 486 PC to allow detection of apnoeas or hypopnoeas when the inspiratory flow/time profile is flattened. Software version 2.0 does not differentiate between apnoeas and hypopnoeas (both taken as more than 50% reduction in flow for at least 10 seconds) in analysis or printout of data, and we have therefore referred to this as the Autoset "apnoea" index. The Autoset system can also be connected to an external oximeter and a Biox 3700 (Ohmeda, Essex, UK) was used in this study.
Polysomnographic variables were scored using our standard criteria for sleep and respiratory signals9 and microarousals.'
DATA ANALYSIS
As the Autoset device does not record sleep, the frequency ofapnoeas and hypopnoeas (Autoset "apnoea" index) obtained with the Autoset was compared with the number of apnoeas and hypopnoeas which occurred either during sleep or during wakefulness on polysomnography.9 Polysomnography was compared with the Autoset using the Wilcoxon rank test, Bland and Altman plots,"3 and correlation analysis.
The results are reported as mean (SE). One observer (NJD) assessed the diagnostic category for each subject based on visual examination of overnight oximetry without reference to Autoset or polysomnography data. Oximetry recordings were categorised as definitely indicative of sleep apnoea/hypopnoea or other.
Results
On polysomnography the patients had a mean (SE) of 25 (4) slept. The number of "apnoeas"/hour in bed obtained by the Autoset was significantly correlated (r=0-85; p<0001) with the number of apnoeas + hypopnoeas/hour in bed obtained on polysomnography ( figure) . The Autoset tended to overscore "apnoeas", median difference 3 1 (95% confidence interval 8-4 to -1*6)/hour in bed, although there was not a statistically significant difference in the number of events scored by the two techniques (p>0 05). Two of the patients had much higher "apnoea" frequencies with the Autoset (69 and 70, respectively) than with polysomnography (34 and 33 apnoeas + hypopnoeas/hour in bed, respectively). These two subjects had 32 and 37 arousals/hour in bed. Examination of the flow signal in these subjects did not show evidence of sustained periods of mouth breathing or dislodgement of nasal cannulae.
If one uses a threshold for disease of ) 15 apnoeas + hypopnoeas/hour of sleep,9 the Autoset gave a sensitivity of 100%, specificity of 92%, the positive predictive value was 92%, and the negative predictive value 100%. Oximetry alone gave a sensitivity of 75%, specificity of 85%, positive predictive value 75%, and negative predictive value 89%. Below 15 apnoeas and hypopnoeas/hour there was poor agreement between the Autoset and polysomnography; however, the diagnostic category of the subjects was not affected.
The cost of consumables for the Autoset system was £2 per subject (for nasal cannulae) compared with £16 per subject with polysomnography. The average time to set up the Autoset system was five minutes compared with 60 minutes for polysomnography. Our night staff did not need to adjust the Autoset system thereafter, whereas polysomnography needs constant attention. Thus, the total recurrent cost of an Autoset study was £7 per study compared with £104 per study for polysomnography (which includes technician costs estimated at £5 for Autoset and £50 for polysomnography). The Autoset costs approximately £10 000 plus VAT and the polysomnography system £22 000. Thus, allowing for five year writedown of capital and 200 studies being performed/bed/year, the cost per study is £14 for the Autoset compared with £126 for polysomnography. This analysis excludes the capital cost of the bed usedidentical for both techniques.
Discussion
The Autoset system was cheap and easy to use and produced data with sufficient accuracy to allow patients with >20 apnoeas + hypopnoeas/ hour of sleep to be confidently diagnosed as having the sleep apnoea/hypopnoea syndrome. However, there was a considerable difference between the results with polysomnography and the Autoset in two patients. We believe that this is due to the Autoset diagnosing "apnoeas" when nasal airflow was continuing, albeit with minor nasal flow limitation," or possibly due to mouth breathing and/or dislodging of nasal cannulae, although we did not notice problems with cannulae positioning. The evidence we have suggests that these particular flow limited events may not have been clinically significant as they were not generally associated with microarousals.3 However, standard electroencephalographic techniques are not always able to detect microarousals which may be more obvious from the recording of cardiovascular sequelae."4 Thus, further data are required before the importance of this discrepancy is clear and at present the Autoset "apnoea" index should be interpreted with caution, especially as the study result is totally dependent on a single parameter -the flow signal (and its quality).
We chose to compare Autoset "apnoeas" with polysomnography apnoeas + hypopnoeas because the distinction between apnoeas and hypopnoeas is somewhat arbitrary'5 and varies between centres. In addition, we suspect that there is inspiratory flow limitation during all clinically significant hypopnoeas and we therefore suspected, and the data show, that the Autoset device was picking up hypopnoeic events.
The Autoset is therefore dignostically useful and superior to oximetry alone. It has the additional advantage over most other limited sleep study equipment that it can also be used to determine the required pressure of continuous positive airway pressure (CPAP) therapy. We have estimated the cost of CPAP titration per patient to be £35 compared with £154 for polysomnography (including disposables, technician time for titration, night/patient, CPAP, education, and capital writedown based on 200 titrations per year).
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